Navigation Links
Rik Deitsch, CEO of Nutra Pharma Creates Personal Wall on WallSt.net's Financial Social Community, my.wallst.net
Date:4/18/2008

NEW YORK, April 18 /PRNewswire-FirstCall/ -- Rik J. Deitsch, Chairman and Chief Executive Officer of Nutra Pharma Corporation (OTC Bulletin Board: NPHC) (http://www.NutraPharma.com) will be updating the investment community through his personal profile on MyWallst.net available at http://www.wallst.net. The dynamic profile will include exclusive interviews with Rik J. Deitsch, company blogs on which investors can comment, his personal stock watchlist, photos of company products and links to recent press.

Visit Rik J. Deitsch's profile on My.wallst.net at http://my.wallst.net/profile.php?ID=20002.

Stay updated about Nutra Pharma Corporation, ask Rik a question or post a comment on his personal page. Join Nutra Pharma's message board to discuss company activity with other interested parties, "invest" in OTCBB: NPHC through the Rookie Challenge and join his financial social network today.

About WallSt.net:

http://www.wallst.net is owned and operated by WallStreet Direct, Inc., a wholly owned subsidiary of Financial Media Group, Inc. (http://www.financialmediagroupinc.com). The Web site is a leading provider of timely business news, executive interviews, multimedia content, and research tools. Financial Media Group, Inc. also owns http://my.wallst.net, a financial social network for investors, and Financial Filings Corp. (http://www.financialfilings.com), a provider of compliance solutions to publicly traded companies. We have received ten thousand dollars from Nutra Pharma Corporation for media and advertising services. In addition to WallSt.net, WallStreet Direct, Inc. owns and operates WallStRadio (http://www.wallstradio.com), a business and finance podcast Web site.

About Nutra Pharma:

Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ('MS'). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.

Contact: Nutra Pharma Corporation

877-895-5647

IR@NutraPharma.com


'/>"/>
SOURCE Nutra Pharma Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Demand for NutraCea Rice Bran Oil Prompts Major Expansion of Irgovel Plant Ahead of Schedule
2. NutraCea-Sponsored Study Demonstrates Benefits of Replacing Wheat Flour with Stabilized Rice Bran (SRB) in Battered and Fried Product Applications
3. NutraCea Appoints New Chief Financial Officer
4. New World Record Holder in Powerlifting Credits NutraCeas Unique Rice-Bran-derived Product as his Secret Weapon
5. Nellson Nutraceutical Names New Directors and Interim Chief Executive Officer
6. NutraCea to Purchase Largest Rice Bran Oil Processing Facility in South America
7. Nutraceutical Reports Fiscal 2008 Q1 Results
8. Neurochem appoints Mr. Gary Schmid as CEO of new nutraceutical business
9. NutraCea Files Universal Shelf Registration Statement
10. NutraCea Provides Update on Domestic Operations
11. Synutra International, Inc. Amends August 2005 Current Report on Form 8-K and Annual Report on Form 10-K for the Fiscal Year Ended March 31, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... May 31, 2016 , ... Like jewels in a crown, the ... – London is home to Ontario’s leading day spa and one of Canada’s few ... began with a unique concept to combine spa services with hair and beauty ...
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... WaterField Designs, ... digital-minded professionals, announces the waxed-canvas and leather Duo Dopp Kit , the ideal ... canvas or ballistic nylon, the Duo is smartly designed for Dad’s grooming ...
(Date:5/31/2016)... , ... May 31, 2016 , ... Spectrum Aquatics has ... new lift has been designed and built with the user in mind. , “Over ... consultants have informed us that an ADA 400 lbs lift is a necessary requirement ...
(Date:5/31/2016)... CA (PRWEB) , ... May 31, 2016 , ... Interest ... a primary screening tool and as an orthogonal tool for RNAi hit validation. A ... functional and specific guide RNAs—allows rapid generation of CRISPR RNA (crRNA) collections in arrayed ...
(Date:5/31/2016)... ... May 31, 2016 , ... TeaZa® Energy, LLC announces ... on World No Tobacco Day . The new flavor—Tropical TeaZa? Energy—will be ... this summer. , The new flavor is best described as a juicy, taste ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... 2016 Since its commercial introduction ... essential life science tool for conducting genetic studies in ... reveals in its new report that the industry sits ... powered by a range of new applications in the ... http://photos.prnewswire.com/prnh/20140723/694805 ) , Since the ...
(Date:5/25/2016)... , Germany and GERMANTOWN, ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: ... licensing and co-development agreement with Therawis Diagnostics GmbH to develop ... be to develop and market PITX2 as a marker to ... high-risk breast cancer patients. "We are pleased to ...
(Date:5/25/2016)... , May 25, 2016 As ... Expo earlier this month, the numbers and momentum of ... to climb into the billions, more research and development ... 4th Edition State of Legal Marijuana Markets Report  from ... data-analysis firm, much of the increase in sector is ...
Breaking Medicine Technology: